Stay updated on VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Sign up to get notified when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.

Latest updates to the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedLocations section added with state-level site listings (Florida, Georgia, Indiana, Kansas, Louisiana, Missouri, New York, North Carolina, Rhode Island, South Carolina, Texas, Utah). Revision: v3.3.3 and removal of the HHS Vulnerability Disclosure element.SummaryDifference1%

- Check21 days agoNo Change Detected
- Check29 days agoNo Change Detected
- Check43 days agoChange DetectedMinor editorial updates: the Publications disclaimer was reworded from 'study results' to 'results of the study', and the revision tag changed from v3.2.0 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedThe government funding status banner warning about potential delays and operating status has been removed from the page.SummaryDifference0.3%

- Check64 days agoChange DetectedThe latest view shows minor layout refinements and reformatting of sections, with no changes to the study title, description, eligibility criteria, primary/secondary outcomes, or listed locations. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check93 days agoChange DetectedThe page now communicates a funding-related operating-status notice and confirms the center is open, plus a new version identifier v3.2.0, replacing v3.1.0.SummaryDifference3%

- Check100 days agoChange DetectedUpdated the page from v3.0.2 to v3.1.0, signaling a new software release version.SummaryDifference0.1%

Stay in the know with updates to VAX-24 Safety and Immunogenicity in Adults Clinical Trial
Enter your email address, and we'll notify you when there's something new on the VAX-24 Safety and Immunogenicity in Adults Clinical Trial page.